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Objective: 
 
To compare vascular risk factor profiles and early outcomes in
all French patients hospitalized for either acute coronary (ACS), or cere-
brovascular syndromes (CVS), or both, between 2005 and 2008.
 
Setting:
 
 All French hospitals.
 
Design
 
: Retrospective analysis.
 
Data sources:
 
 National database called “Hospital Discharge Diagnosis
Records”.
 
Main outcomes measured:
 
 Number and annual rates, vascular risk factors,
and early outcome of hospitalized patients for a unique stay for ACS or CVS
or for both ACV and CVS in a 2-month time window.
 
Results: 
 
Over the 4-year study-period, 1,189,043 patients were hospital-
ized for CVS and/or ACS. Among these, 638,061 (53.7%) had CVS alone,
525,419 (44.3%) had ACS alone, and 24,163 (2%) had both. Patients of the
latter group were older (75.2 ± 12 years), and had a higher prevalence of
hypertension (50.8%), diabetes (26.3%), and atrial fibrillation (23.9%)
(p<0.001). In contrast, the prevalence of obesity (9.6%) and hypercholester-
olemia (25.7%) was greater in ACS only patients. Patients with both CVS
and ACS had a longer length of stay (16.1 days), and were less likely to be
discharged to home. These patients also had a higher in-hospital risk of
death, in men and in women (Figure). This risk remained after adjustment
for age, sex, and vascular risk factors compared with patients with either
CVS alone (OR=1.71, 95% CI: 1.66-1.77) or ACS alone (OR=2.95, 95% CI:
2.85-3.05).
 
Conclusion: 
 
Our study conducted in almost 1.2 million hospitalized
patients provides clear evidence that patients with both CVS and ACS have a
high vascular risk profile and a marked excess risk of early death.
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Metabolic syndrome is associated with an increased risk of coronary heart
disease (CHD), but it is still debated whether it could act as an independent
risk factor per se. We compared the respective values of metabolic syndrome
and its components to predict presence of CHD.
 
Methods:
 
 A case control study was conducted in 2001-2004, including
748 cases (French male patients with a history of CHD) and 810 controls from
the general population. Data on medical history and cardiovascular risk factors
were collected. Two logistic regression models were built to predict the prob-
ability to be a case (to have CHD). The first one considered metabolic syn-
drome as explanatory variable. In the second one, metabolic syndrome was
replaced by its components (high blood pressure or antihypertensive drug use,
waist circumference, high glycemia or hypoglycemic drug use, plasma triglyc-
erides and HDL-cholesterol). Both models were adjusted for age, level of edu-
cation, physical activity, smoking and LDL-cholesterol.  
 
Results:
 
 Participants were aged 45-75 years old, 45.4% of cases and 18.6%
of controls had a metabolic syndrome. The sensitivity and the specificity of the
first model to predict CHD were 81% and 62%, respectively, and the c-sta-
tistic reached 0.79 [95% CI: 0.76-0.80]. In the second model, sensitivity, spec-
ificity and c-statistic were 82%, 67% and 0.85 [0.83-0.86], thus leading to a
better discrimination. Among cases, 5.6% were adequately reclassified by the
second model (0.7% non adequately reclassified). Among controls, 16.3%
were adequately reclassified, without any wrong reclassification. Overall, the
second model led to an improved net reclassification of 4.9% in cases and
16.3% in controls, compared to the first model. 
 
Conclusions:
 
 Using the components of the metabolic syndrome in algo-
rithms to predict presence of CHD is better than using metabolic syndrome as
a whole entity. This result should improve the screening of people who are
likely to suffer from silent CHD. 
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Correlation between perceived cardiovascular risk (CVR) by physicians
and real CVR is poorly known. Moreover, the underlying question of factors
associated to risk misevaluation, especially for patients at high CVR and that
could benefit of a lipid lowering therapy (LLT), remains unsolved.
 
Objective and methodology: 
 
This was an on-line non-interventional study
conducted on a sample of 619 general practitioners. The aim was to describe
the relation between physicians evaluated CVR and calculated CVR according
to risk’s scales. All consulting patients’ aged50 years old (YO) were included.
Physicians had to complete a questionnaire and to assess patient’s CVR on a
3 level scale (low, medium, and high). Framingham and SCORE (low
risk<2%, high risk5%) were calculated. 
 
Results: 
 
13446 patients were included (mean age: 67 YO, male: 48%,
LDLc1.3g/L: 46%, LLT: 36%, personal history of CV disease: 16%, smoker:
12%, high blood pressure (HBP): 52%, diabetes: 18%). 
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Physicians evaluation mismatched with Framigham for 50% of the patients
and 27% were under-evaluated. Evaluation mismatched with SCORE for 53%
of the patients, 38% were under-evaluated. Within the 25% of the patients
having a Framingham score >20% and without a lipid lowering treatment,
70% was under evaluated by physicians. Within the 38% of the patients
having a SCORE calculation 5% and without a lipid lowering treatment, 78%
were under evaluated.
 
Conclusion: 
 
This study underlines the mismatch between GP perceived
CVR and calculated CVR, especially for high CVR patient. Males, patients
with treated HBP and with high LDL-c were at increased risk of CVR under-
evaluation.
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Background:
 
 The French guidelines recommend dual antiplatelet therapy
after acute myocardial infarction (MI). 
 
Purpose:
 
 To estimate persistence of dual antiplatelet therapy after MI.
Methods: A cohort study was conducted using data from the main French
health insurance reimbursement database of the Aquitaine region (southwest
France). Patients who have been hospitalized for MI in 2008 were first iden-
tified. Then, we looked for their reimbursement form of dual antiplatelet
therapy (aspirin+clopidogrel) treatment for the following 12 months. Adher-
ence was assessed by using two parameters: proportion of days covered by
the treatment (medication availability) and persistence. The treatment persis-
tence was the percentage of patients still treated at the end of the period.
Discontinuation was defined as a minimum gap of 30 days between the the-
oretical end date of prescription reimbursed (based on a days’ supply) and
the starting date of the next one. 
 
Results:
 
 Among the 634 patients identified, 40 had no reimbursement
of dual antiplatelet therapy immediately after discharge. At three month,
15.2% of the remaining patients did not buy at least one of the two treat-
ments. They were 48.2% at 12 months although the medication availability
was 90%. Conclusion: Theses results suggest that while the patients have
good medication availability, the treatment is often stopped before one
year. At three months after MI, 20.6% of the patients were no longer
treated with dual antiplatelet therapy. The results presented are likely to be
an underestimation of adherence since some patients who buy their treat-
ment, may not take it. This could explain some “resistance” described to
antipletelet therapy.
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Purpose:
 
 Chronic Obstructive Pulmonary Disease (COPD) is expected to be
the third cause of mortality in the world in 2020. Paradoxically, this disease is
widely underdiagnosed and its prevalence remains relatively unknown, in partic-
ular in people at cardiovascular risk for whom the association with COPD may
worsen the prognosis. The aim of this study was to assess COPD prevalence in a
population at cardiovascular risk and to analyse determinants of COPD.
 
Methods: 
 
Our study was based on patients referred for cardiovascular
check-up to a Preventive Cardiology Clinic in a University Hospital in 2009.
Participants answered to questionnaires on socio-economic level, medical his-
tory and life style. They completed an extensive physical examination and a
spirometry test. COPD prevalence was based on the spirometric classification
proposed by the Global Initiative for chronic Obstructive Lung Disease. Deter-
minants of COPD were assessed with logistic regression. 
 
Results:
 
 The sample comprised 502 participants (mean age: 57.4 ±11.1 years),
including 60% of men, 17% of current smokers, 42% of former smokers and 10%
of patients with a history of cardiovascular disease (ischemic heart disease, cere-
brovascular or peripheral arterial disease). Ten-year risk of coronary heart disease
according to the Framingham equation was intermediate (10-20%) for 33% of
patients and high (> 20%) for 5%. After exclusion of asthmatic patients, 5.8%
[95% CI: 3.9% - 8.2%] were spirometrically
 
 
 
screened as COPD patients (Forced
Expiratory Volume in one second / Forced Vital Capacity < 0.70). After adjust-
ment for age, gender and smoking, the odds ratio for COPD was 4.44 [1.83-10.78]
(p-value=0.001) in patients with a history of cardiovascular disease compared to
those without. Besides, 86% of the patients screened with COPD had never been
previously diagnosed.
 
Conclusion:
 
 Patients with cardiovascular disease are at increased risk of
COPD and thus should beneficiate from COPD screening.
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Introduction:
 
 Cardiovascular diseases are the leading cause of mortality in
the western countries at the same time they are beginning to appear with
increasing frequency in developing countries. With the epidemiological transi-
tion phenomenon, Tunisia is now facing the growing prevalence of chronic
diseases. The Tunisian epidemiological data on cardiovascular disease in the
 
Population risk is listed below
 
 Evaluated (%) Framingham (%) Score (%)
Low 
 
40 41 28
 
Medium 
 
37 24 24
 
High
 
23 35 48
 
Explanatory factors for under-evaluation in primary prevention according to 
SCORE 
 
 OR CI 95%
Treated HBP vs no HBP
 
2,55 2.04-3.19
 
Gender (male)
 
2,44 2,16-2,76
 
 LDLc
 
2,13 1,78-2,55
 
Smoker
 
1,82 1,52-2,19
 
Chronic inflammatory disease
 
1,19 1,00-1,42
 
Age
 
1,16 1,15-1,17
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